Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
David Einhorn's Trump-Proof Investment Plan
18 Stocks Moving In Friday's Pre-Market Session
The Last Retail Store (Seeking Alpha)
Related PFE
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Incyte PDUFA Date Pushed Back, JMP Discusses Impact
Make Your Dogs Of The Dow Howl (Seeking Alpha)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Jan 2017JefferiesDowngradesBuyHold
Jan 2017Standpoint ResearchUpgradesHoldBuy
Dec 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

View Comments and Join the Discussion!